At 28 years old, Dave Carbonell was months away from completing his residency in Emergency Medicine at UNC. Then cancer struck – acute lymphoblastic leukemia. Today, after years of intense treatment, he’s cancer free, working as an Emergency Department physician in California and helping other young adults during their cancer journey.
In a study published in journal Nature Immunology, researchers led by UNC Lineberger member Jenny P.Y. Ting, PhD, describe how inflammation can go unchecked in the absence of a certain inflammation inhibitor called NLRP12. In a harmful feedback loop, this inflammation can upset the balance of bacteria living in the gut. Beneficial bacterial may be the key to reversing inflammation in the absence of this key regulator.
H. Shelton Earp, MD, director of UNC Cancer Care and the Lineberger Professor of Cancer Research, and Jenny P.Y. Ting, PhD, UNC Lineberger member and William Rand Kenan Professor of Genetics, have been honored with the Hyman L. Battle Distinguished Cancer Research Award.
The early-stage cellular immunotherapy trials are for patients with either Hodgkin lymphoma or non-Hodgkin lymphoma, who lack other treatment options or are at high risk of their disease returning.
UNC Lineberger researchers Hy Muss, MD, Shlomit Strulov Shachar, MD, and colleagues report in the journal Clinical Cancer Research that a measure of muscle mass and muscle quality developed at UNC could potentially help doctors better identify patients at high risk for side effects that could require hospitalization.
Using dye to map cancer metastases, Emma Rossi, MD, and UNC collaborators lead large study to help patients avoid complications from surgery.
A study led by UNC Lineberger researcher Ronald Chen, MD, found that a group of prostate cancer patients reliably reported their own medical histories when their responses were compared to their medical records.
With a $1.74 million grant from the NIH, UNC Lineberger researchers led by H. Shelton Earp, MD, will study a potential new strategy for improving immunotherapy drug responses in patients with melanoma.
UNC-Chapel Hill researchers led by UNC Lineberger member Shawn Hingtgen, PhD, reach a critical milestone for treating brain cancer.
UNC Lineberger researchers find how triple negative breast cancer cells are able to bypass treatment with trametinib, an FDA-approved drug. The researchers also used lab models of breast cancer to test a potential treatment approach that could prevent resistance.
UNC Lineberger researchers Ethan Basch, MD, MSc, and Stephanie Wheeler, PhD, MPH, called for tailored, local-level cancer prevention, screening and treatment efforts to address regional disparities in cancer mortality rates in an editorial published in JAMA on Tuesday.
UNC, NCSU biomedical engineering research team’s findings show that engineered platelets can deliver antibodies to kill cancer cells before they can grow or spread elsewhere in the body.
Unmasking a previously misunderstood gene, University of North Carolina scientists discover an unlikely potential drug target for gastrointestinal cancers.
In a perspective published in the New England Journal of Medicine, Ethan Basch, MD, MSc, professor of medicine and director of UNC Lineberger’s Cancer Outcomes Research Program, addressed the need for – and the barriers preventing – electronic reporting of patients’ symptoms between visits.
UNC scientists led by John Sondek, PhD, created a new biochemical tool to block specific types of downstream G-protein signaling, opening new avenues of research and potential drug design and discovery.
UNC Lineberger researchers reported at the San Antonio Breast Cancer Symposium they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2-positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy.
Less than 50 percent of surveyed teens found it ‘very believable’ that cigars are not a safe alternative to cigarettes, according to a first-of-its-kind UNC School of Medicine study.
In preliminary findings presented at the 2016 San Antonio Breast Cancer Symposium, researchers showed that older patients were as likely as younger patients to receive targeted therapy and enroll in therapeutic trials based on their sequencing results.
In a study presented at the 2016 San Antonio Breast Cancer Symposium, UNC Lineberger researchers led by Katherine Hoadley, PhD, reported they developed a model that can predict which triple negative breast cancer patients will respond to chemotherapy.
At this year's San Antonio Breast Cancer Symposium, UNC Lineberger researchers and collaborators shared the outcomes of their investigation into the incidence of brain metastasis after a series of drugs were approved to treat HER2-positive metastatic breast cancer, starting with trastuzumab, also known as Herceptin, in the United States in 1998.